Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PO0T
|
|||
| Drug Name |
BMS-986036
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb Princeton, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor-21 (FGF21) | Target Info | Agonist | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Melanoma | ||||
| Reactome | Facilitative Na+-independent glucose transporters | |||
| Glucose transport | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Aryl Hydrocarbon Receptor | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.